These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 11373776)

  • 1. [Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():39. PubMed ID: 11373776
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-nucleoside reverse transcriptase inhibitors--an overview.
    Bell C; Matthews GV; Nelson MR
    Int J STD AIDS; 2003 Feb; 14(2):71-7. PubMed ID: 12662384
    [No Abstract]   [Full Text] [Related]  

  • 3. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
    van Leth F; Lange JM
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efavirenz--comprehensive status of studies].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():79-81. PubMed ID: 16385886
    [No Abstract]   [Full Text] [Related]  

  • 5. Factors affecting adherence and convenience in antiretroviral therapy.
    Lafeuillade A
    Int J STD AIDS; 2001 Nov; 12 Suppl 4():18-24. PubMed ID: 11589824
    [No Abstract]   [Full Text] [Related]  

  • 6. NNRTI hepatotoxicity: efavirenz versus nevirapine.
    Pulido F; Torralba M
    J HIV Ther; 2002 Nov; 7 Suppl 2():S3-16. PubMed ID: 12735215
    [No Abstract]   [Full Text] [Related]  

  • 7. The tolerability of efavirenz after nevirapine-related adverse events.
    Clarke S; Harrington P; Barry M; Mulcahy F
    Clin Infect Dis; 2000 Sep; 31(3):806-7. PubMed ID: 11017835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV/AIDS news: comparable anti-HIV antiviral efficacy of Viramune and Efavirenz--the Lancet publishes first large-scale comparison study.
    Meyer-Kleinmann J
    Infection; 2004 Jun; 32(3):7. PubMed ID: 15230276
    [No Abstract]   [Full Text] [Related]  

  • 9. [Antiretroviral therapy. NNRTI (non-nucleoside reverse transcriptase inhibitor)].
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():14-6. PubMed ID: 10863304
    [No Abstract]   [Full Text] [Related]  

  • 10. Substitution for protease inhibitors in HIV therapy.
    Hirschel B
    N Engl J Med; 2003 Dec; 349(25):2460-1; author reply 2460-1. PubMed ID: 14681514
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of NNRTIs in antiretroviral-naïve patients.
    Arribas J
    Int J STD AIDS; 2001 Nov; 12 Suppl 4():3-9. PubMed ID: 11589822
    [No Abstract]   [Full Text] [Related]  

  • 12. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
    Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What they say about non-nucleoside drugs.
    Posit Aware; 1999; 10(1):35-7. PubMed ID: 11366521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efavirenz].
    Taéron C
    Rev Infirm; 2005 May; (111):37-8. PubMed ID: 15991644
    [No Abstract]   [Full Text] [Related]  

  • 15. [Protease inhibitor saving alternatives].
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():16-7. PubMed ID: 10863305
    [No Abstract]   [Full Text] [Related]  

  • 16. [Reliable effectiveness for years with good long-term tolerance: 10 years nevirapine--a summary].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():70. PubMed ID: 19024921
    [No Abstract]   [Full Text] [Related]  

  • 17. [Didanosine--stability as backbone drug].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():83-4. PubMed ID: 16385888
    [No Abstract]   [Full Text] [Related]  

  • 18. [Non-nucleoside reverse transcriptase inhibitor as a fully viable alternative. Strong therapy start without protease inhibitor].
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():30-3. PubMed ID: 10863307
    [No Abstract]   [Full Text] [Related]  

  • 19. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
    Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
    HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.
    Wolbach J; Capoccia K
    Nurse Pract; 1999 Jun; 24(6):81-2, 87-90, 92. PubMed ID: 10431297
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.